Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01668511 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-981 in Patients With Osteoarthritis of the Knee

A Phase 1 study, sponsored by AbbVie (prior sponsor, Abbott).

Completed
Registry status
Phase 1
Development phase
36
Enrollment target

NCT01668511 is a Phase 1 study that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 36 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01668511, a Phase 1 study, has completed, sponsored by AbbVie (prior sponsor, Abbott).

COMPLETED
Registry status
Phase 1
Development phase
36 participants
Enrollment target

Study Summary

To assess the safety, tolerability and pharmacokinetics of ABT-981 in patients with osteoarthritis of the knee.

Interventions

  • BIOLOGICAL Placebo
  • BIOLOGICAL ABT-981

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2012-09
Est. Completion 2013-10
Phase Phase 1

Sponsor

AbbVie (prior sponsor, Abbott)

88 total trials

What the Registry Record Tells You About NCT01668511

The ClinicalTrials.gov registry entry for NCT01668511 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie (prior sponsor, Abbott), which has 88 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT01668511 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01668511 about?

NCT01668511 is a clinical study titled "A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-981 in Patients With Osteoarthritis of the Knee". To assess the safety, tolerability and pharmacokinetics of ABT-981 in patients with osteoarthritis of the knee.

What is the current status of trial NCT01668511?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2012-09. Estimated completion is 2013-10.

What interventions are being tested in trial NCT01668511?

The interventions under investigation include: Placebo (BIOLOGICAL), ABT-981 (BIOLOGICAL).

Who is sponsoring clinical trial NCT01668511?

This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.